Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | terminated | Phase 1 / Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Kathy MillerOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | terminated | Phase 2 | 1 | BTG International Inc.OTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | terminated | Phase 2 | 137 | Boston Scientific CorporationINDUSTRY | 4 | Jun 22, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 12 | Elevar TherapeuticsINDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) | terminated | Phase 2 | 67 | AIO-Studien-gGmbHOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | terminated | Phase 2 | 10 | Zhejiang UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | terminated | Phase 2 | 7 | SC Liver Research Consortium, LLCOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma(GCC 1314) | terminated | Phase 2 | 3 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | terminated | Phase 2 | 15 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | terminated | Phase 2 | 8 | Burzynski Research InstituteOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype | terminated | Phase 2 | 5 | Chang Gung Memorial HospitalOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging | terminated | Phase 2 | 3 | University of Alabama at BirminghamOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib | terminated | Phase 2 | 5 | Gachon University Gil Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | terminated | Phase 2 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | terminated | Phase 2 | 1 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT01367275 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | terminated | Phase 1 / Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | terminated | Phase 2 | 9 | CCTU- Cancer ThemeOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery | terminated | Phase 2 | 8 | Eben RosenthalOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | terminated | Phase 2 | 5 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | terminated | Phase 2 | 17 | Beth Israel Medical CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 29 | Taiwan Liposome CompanyINDUSTRY | 2 | Feb 26, 2019 | clinicaltrials |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | terminated | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | terminated | Phase 2 / Phase 3 | 79 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2018 | clinicaltrials |
| NCT02234180 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery | terminated | Phase 2 | 3 | Academic and Community Cancer Research UnitedOTHER | 1 | Oct 17, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2022source: clinicaltrials